Cartier Esham’s Testimony to Energy and Commerce Health Subcommittee on Treatments and Cures for Neurodegenerative Diseases
July 30, 2021
BIO regularly publishes reports that help us assess the health of the biopharmaceutical pipeline across different diseases so that we can identify and remove barriers to providing next generation cures and treatments to patients and their families. I will highlight three such analyses with a focus on neurology clinical development programs (pipeline, investment and clinical trial success rates) with the goal of providing helpful insights to this important conversation. Later I will do a deeper dive into Alzheimer’s Disease as an example of the state of innovation for neurodegenerative diseases.
Download Full Comments Below
Testimony to Energy and Commerce Health Subcommittee on Treatments and Cures for Neurodegenerative Diseases
In response to their advance notice of proposed rulemaking (ANPRM), BIO submitted comments to the DOJ's National Security Division on implementing the White House Executive Order of February 28, 2024, “Preventing Access to Americans’ Bulk Sensitive…
We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry…
BIO regularly publishes reports that help us assess the health of the biopharmaceutical pipeline across different diseases so that we can identify and remove barriers to providing next generation cures and treatments to patients and their families. I will highlight three such analyses with a focus on neurology clinical development programs (pipeline, investment and clinical trial success rates) with the goal of providing helpful insights to this important conversation. Later I will do a deeper dive into Alzheimer’s Disease as an example of the state of innovation for neurodegenerative diseases.